Event
Bio-Neuroscience
Date: 24-26 February 2026
 Location: Amsterdam, Netherlands
Katie Headland, Senior Director
Business Development UK
Aurelie Dos Santos,
Business Development Associate BD & Sales Benelux
Engaging the CNS Community
Axxam is attending Bio‑Neuroscience, a Broadreach Global meeting that brings together leaders from biotech, pharma, investment, and patient organizations to discuss the strategic and translational challenges of CNS drug development.
Unlike large scientific congresses, Bio‑Neuroscience is designed for high‑level dialogue and partnering, focusing on how scientific insight, development strategy, and execution come together to advance therapies for neurological and psychiatric disorders. In this context, Axxam participates as a discovery partner contributing experimental perspective to early‑stage CNS decision‑making.
Why Bio‑Neuroscience matters for CNS Programs
CNS drug discovery faces persistent hurdles: limited translational predictivity, complex disease biology, and high attrition rates. Addressing these challenges requires not only innovative science, but also clear, well‑interpreted experimental data that can support strategic choices early on.
Bio‑Neuroscience creates space for open discussion around:
- Confidence in CNS research
- Early go/no‑go decision criteria
- Alignment between biology, discovery strategy, and development goals
Supporting early and strategic decisions
At Bio‑Neuroscience, the focus is not on data volume, but on decision‑enabling insight. Axxam aligns with this mindset by supporting early discovery programs through:
- Carefully designed screening and follow‑up strategies
- Integration of functional data with orthogonal evidence
- Experimental input that supports prioritization and strategic discussion
Our goal is to help CNS teams move forward with greater clarity and confidence at critical early stages.
Meet Axxam at Bio‑Neuroscience
Bio‑Neuroscience offers a unique setting for focused conversations among CNS leaders, innovators, and decision‑makers.
We look forward to engaging with attendees to exchange perspectives on CNS discovery challenges, experimental strategies, and how early data can better support long‑term development success.
Whether you are exploring new targets, confirming mechanisms, or scaling up screening efforts, our team is ready to discuss how Axxam can support your Alzheimer’s or Parkinson’s drug discovery program.